SAN FRANCISCO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges DexCom, Inc. (NASDAQ: DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. On July 26, 2024, the price of DexCom shares cratered $43.85 (-40%) after the company announced Q2 2024 financial results and outlook that significantly disappointed investors and analysts. Unsurprisingly, downgrades followe ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Sept. 12, 2024 /PRNewswire/ - ...

The stock isn't normally this cheap, and investors should take advantage.DexCom (DXCM -1.27%) is a big name in diabetes care. Its continuous glucose monitors (CGMs) help people track their blood glucose levels.But the stock has been performing poorly this year amid falling growth (the company projects an organic growth rate of around 11% to 13%, far lower than in the past). Investors have also been growing concerned about its prospects, especially if weight loss drugs can lead to a reduction in diabetes cas ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=101880&from=4CLASS PERIOD: January 8, 2024 to July 25, ...

RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is October 21, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered DexCom losses, you may  ...

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

文章核心观点 1) 公司面临三大挑战:客户增长放缓、收入下降、国际业务表现不佳 [3] 2) 公司还面临来自竞争对手的压力,以及体重减轻药物对糖尿病增长的潜在影响 [3] 3) 公司管理层信任受损,因为公司在6月份会议上重申了指引,但在7月份却下调了指引 [3] 4) 分析师大幅下调了公司的目标价格,这是今年最大的目标价格下调之一 [4] 公司优势 1) 公司在连续血糖监测(CGM)行业处于领先地位,在1型和2型糖尿病细分市场都有很大的增长潜力 [5] 2) 公司在CGM行业开创了多项创新,如首次获得专用应用程序、首次获得直接连接苹果手表等 [5] 3) 公司正在开发新产品Stelo,针对2型非胰岛素依赖性糖尿病患者 [6] 4) 公司正在改进G7 CGM系统,预计2025年获得FDA批准 [6] 行业前景 1) 全球CGM市场在今年上半年增长约22%,预计将保持较高增长 [8] 2) 根据国际糖尿病联盟数据,糖尿病患者数量有望在2045年达到7.83亿 [9] 估值分析 1) 分析师下调了公司未来几年的盈利增长预期,从15-27%下调至13-19% [10] 2) 考虑到增长预期下调和不确定性增加,公司合理估值应为40倍市盈率,对应股价96美元 [11]

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=101243&from=3 CLASS PERIOD: January 8, 2024 to J ...

RADNOR, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024. CONT ...

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline in the securities class action. SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...